8-K 1 j0777701e8vk.htm RESPIRONICS, INC. 8-K
Table of Contents

SECURITIES AND EXCHANGE COMMISSION
 

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 21, 2004

RESPIRONICS, INC.

(Exact name of Registrant as specified in its charter)

         
Delaware   000-16723   25-1304989
  		 
  		 
 
(State or Other Jurisdiction of   (Commission File   (I.R.S. Employer
Incorporation)   Number)   Identification Number)
         
1010 Murry Ridge Lane        
Murrysville, Pennsylvania       15668-8525
  		     
 
(Address of Principal        
Executive Offices)       (Zip Code)

724-387-5200

(Registrant’s telephone number, including area code)

 

TABLE OF CONTENTS

         
    Page
    2  
    3  
    4  
 Press Release

 

Table of Contents

Item 9. REGULATION FD DISCLOSURE.

     On May 21, 2004, Respironics, Inc. issued a press release announcing that it will make an offer to acquire for cash the issued share capital of Profile Therapeutics plc (London SE symbol: PTP) for 50.9 pence per share or a total of approximately $44.6 million, at the current exchange rate. A copy of the press release is attached hereto as Exhibit 99.

Exhibits

99   Press release, dated May 21, 2004, issued by Respironics, Inc.

2

Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    RESPIRONICS, INC.
 
        
  By:   /s/ Daniel J. Bevevino
 
       
     
 
      Daniel J. Bevevino
      Vice President, and Chief Financial and
      Principal Accounting Officer
Dated: May 21, 2004
        

3

Table of Contents

INDEX TO EXHIBITS

     
Exhibit No.   Description
     
99
  Press release, dated May 21, 2004, issued by Respironics, Inc.

4